PRostate Olaparib Real World Evidence Study (PROWESs)

AstraZeneca

Status: Enrolling

Conditions: Metastatic Castration-resistant Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT06031805

D0817R00049

Details and patient eligibility

About

This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.

Enrollment: 300 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult male patients (≥ 18 years old)
• With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician
• Who have been informed and are not opposed to this data collection

Exclusion criteria

• Patients opposed to the collection of their data
• Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation